Enzyme-Based Scissors Target Cancer Cell Defenses: Researchers at Stanford University Reveal

The biomolecule's ability to degrade mucins on cancer cells represents a significant advancement in the fight against cancer, offering new avenues for effective and targeted treatment options.

In a groundbreaking discovery, researchers at Stanford University have engineered a remarkable biomolecule that could revolutionize cancer treatment. This newly developed biomolecule acts like a pair of scissors, specifically cutting away sugar-coated proteins known as mucins from cancer cells. By stripping these mucins, the biomolecule exposes cancer cells to the immune system, potentially paving the way for more effective cancer therapies.

 

Mucins are normally beneficial proteins coated with sugar molecules, serving as the body's defense against physical harm and pathogens. However, cancer cells have found a way to exploit mucins, using them as a shield against the immune system. Removing mucins from cancer cells could be a potential strategy for cancer therapy. However, since mucins are present in various forms throughout the body, targeting them without precision might have unintended consequences.

 

The solution devised by the Stanford-led research team involves creating an enzyme-based scissors. This unique biomolecule combines a mucin-cutting enzyme called mucinase with a cancer-cell-targeting nanobody, a fragment of an antibody. Together, these components selectively target and remove mucins from specific cancer cells.

 

The study's results, published in Nature Biotechnology, demonstrated the biomolecule's potential. In lab-grown human cancer cells and simulated mouse studies of breast and lung cancer, the biomolecule treatment significantly reduced tumor growth and improved survival rates. This breakthrough has far-reaching implications, as mucins are associated with a range of diseases beyond cancer, including respiratory conditions and viruses.

 

Senior author Carolyn Bertozzi, a respected figure in the field, explained the significance of their findings. "We found that we could target this mucinase to cancer cells, use it to remove mucins from those cancer cells, and there was a therapeutic benefit," she stated.

 

The co-lead author of the study, Gabrielle Tender, along with former members of Bertozzi's lab, Kayvon Pedram and D. Judy Shon, collaborated to develop this innovative approach.

 

Mucins, while usually beneficial, can contribute to cancer progression when misused by cancer cells. One function involves helping cancer cells survive in environments where they are not firmly attached. Additionally, cancer cells can employ mucins to bind to immune system checkpoint receptors, avoiding detection and immune response.

 

The biomolecule designed by the research team is a fusion of two parts. The first part, the mucinase, cleaves mucins, while the second part, a cancer-specific nanobody, targets cancer cells. This nanobody guides the mucinase to cancer cells, ensuring that it only removes mucins from these cells.

 

The study's success brings us one step closer to potential new cancer therapies. The next challenge is to develop a human-derived mucinase, as the current version is not human-derived and may trigger unwanted immune responses.

While more research is needed before this approach can be implemented in clinical settings, this breakthrough holds immense promise. The biomolecule's ability to degrade mucins on cancer cells represents a significant advancement in the fight against cancer, offering new avenues for effective and targeted treatment options.

Tags : #StanfordUniversity #Mucins #biomolecule #advancement #NatureBiotechnology

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Will India’s Healthcare Budget Support a Future of Robotic Surgeries?February 22, 2025
Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat VirusFebruary 22, 2025
Newcastle University Expands Academic and Research Collaborations in IndiaFebruary 21, 2025
Get Ready to #BibaUp! Kriti Sanon Unveils the Season’s Most Stylish Summer CollectionFebruary 21, 2025
A Rare Condition: Surgery Saves 2-Day-Old Baby as Organs Shift Into ChestFebruary 21, 2025
Odisha’s Bold Healthcare Vision: A Rs 12,000 Crore Blueprint for Universal Health AccessFebruary 21, 2025
Young India’s Health Crisis: Why Insurance Claims Are Rising Among 25-35 Year OldsFebruary 21, 2025
India vs. Trump’s Pharma Tariff: The Battle Over Affordable MedicineFebruary 21, 2025
Foreign Medical Aspirants in Trouble: NMC’s Warning on Pending Eligibility CertificatesFebruary 21, 2025
Think Your Work Music Helps You Focus? Science Says Think AgainFebruary 21, 2025
Is Your Home’s Air Poisoning You? Shocking New Study Reveals Hidden Indoor Pollution RisksFebruary 20, 2025
The Society of Automotive Engineers & B V Raju Institution of Technology; to host the globally prestigious E-BAJA 2025; at Hyderabad!February 20, 2025
Eat right for your heart to beat rightFebruary 19, 2025
Aakash Healthcare and Medtronic Inaugurate North India’s First Dedicated Vein ClinicFebruary 19, 2025
Urgent and accelerated HIV service delivery with equity and rights is critical to end AIDSFebruary 19, 2025
Fasting Fad or Future Health Threat? Why Teens Should Think Twice Before Intermittent Fasting February 19, 2025
Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery WaveFebruary 19, 2025
Screen Time and Healthy Habits: Navigating Optimal Development in ChildrenFebruary 18, 2025
SRM Global Hospitals Launches WOW, a Centre Exclusively for Women’s Health and WellnessFebruary 18, 2025
The Hidden Dangers of Scented Candles: Aesthetic Bliss or Silent Health Hazard?February 18, 2025